FDA Adds a Rare Eye Condition Warning to Every GLP-1 Medicine Label, From Ozempic and Zepbound to Foundayo

Last week the FDA told the makers of every GLP-1 medicine to add a warning about a rare eye condition called NAION. Here is what the agency found, what it says to watch for and why it is not telling people to quit.

Order Meals — View This Week's Menu

By Lew Kizer — 2026-11-17 — Health & Nutrition

The short answer

On Nov. 9, 2026, the FDA required makers of all GLP-1 medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda and Foundayo, to add a warning about a potential increased risk of NAION, a rare optic nerve condition that can cause sudden, painless vision loss in one eye. The FDA calls the risk potential and rare. Anyone who notices sudden vision changes should contact a health care professional right away, and should not stop their medicine without talking with their provider first.

Key facts

  • The FDA announced the class-wide labeling change in a Drug Safety Communication on Monday, Nov. 9, 2026.
  • The warning goes in the Warnings and Precautions section of every GLP-1 receptor agonist label, including semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide and orforglipron.
  • NAION (non-arteritic anterior ischemic optic neuropathy) can cause sudden, painless decreased vision in one eye, including permanent vision loss.
  • In an analysis of 126 clinical trials with more than 134,000 patients, there were 15 probable NAION events: about 6.4 per 100,000 person-years on GLP-1 medicines vs. 3.8 on placebo.
  • In an FDA Sentinel study of people with type 2 diabetes, the rate on GLP-1 medicines was not significantly different from SGLT-2 drugs but was higher than DPP-4 drugs.
  • Europe's medicines agency listed NAION as a very rare side effect of semaglutide in June 2025. The FDA action covers the whole class.
  • Novo Nordisk says the data do not establish cause and effect. Lilly says the notice does not reference findings specific to its medicines.

KINGSPORT, Tenn., Nov. 17, 2026 — Last Monday, Nov. 9, the FDA told the makers of every GLP-1 medicine to add a new warning to their labels about a rare eye condition called NAION. That covers the big names, Ozempic, Wegovy, Mounjaro and Zepbound, plus the newer Foundayo pill. The agency's Drug Safety Communication calls the risk potential and rare. A week later, the questions we hear are simple: what is it, how worried should I be and should I keep taking my medicine?

This article reports medical news and is not medical advice. SmashMeals is a food company, not a medical provider, and is not affiliated with the companies, agencies or researchers named here. Talk with your prescriber before you start, stop or change any medicine.

What changed

The FDA required every GLP-1 medicine maker to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of the label, according to Pharmacy Times and Ophthalmology Times. NAION can cause sudden, painless loss of vision in one eye, and the loss can be permanent.

The list covers semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda, and Xultophy with insulin), lixisenatide with insulin (Soliqua), generic exenatide and orforglipron (Foundayo).

What the FDA looked at

Concern started with a 2024 study in JAMA Ophthalmology that linked semaglutide with NAION. The FDA called that study limited but worth a closer look. Then came two bigger checks:

Put plainly: even on a GLP-1, these numbers mean a handful of cases per 100,000 people per year. Ophthalmology Times notes the evidence is limited and hard to read, because diabetes and other conditions these drugs treat are risk factors for NAION too. Europe's medicines agency listed NAION as a very rare side effect of semaglutide in June 2025; the FDA action goes further by covering the whole class.

What the FDA says to do

The FDA tells prescribers to have patients report right away any sudden, painless loss of vision, blind spots or other vision changes in one eye, and to send suspected cases promptly to an eye specialist. Prescribers can consider stopping the medicine in someone who develops NAION unless the benefits clearly outweigh the risk.

For patients, the FDA told Healthline that anyone with sudden, painless vision loss in one eye "should contact their healthcare professional immediately and should not stop their medication without consulting their provider first."

The companies responded to ABC News. Novo Nordisk said it "continues to believe the data do not establish a cause-and-effect relationship." Lilly said the FDA notice "does not reference any findings specific to Lilly medicines" and that it will respond to the FDA promptly.

Where food fits, and where it does not

This is a medicine safety story, not a diet story. No meal plan changes this risk, and we will not pretend otherwise. What we can help with is the part of a GLP-1 routine that happens three times a day: smaller appetite, protein that has to fit into less food and meals you do not have to think hard about.

If that is where you are, start with our GLP-1 meal planning page, the Wegovy meal plan or the illustrative 7-day GLP-1 meal plan. None of it replaces advice from your prescriber or a registered dietitian.

“When you're on a GLP-1 medication, what you eat matters more, not less. You need high-protein, portion-controlled, nutrient-dense food — and you need to know it's safe. That's exactly what we do.” — Lew Kizer, Founder, SmashMeals

Pick up locally or order for shipping; checkout confirms timing. See this week's meals.

Commentary, not medical advice

The SmashMeals perspective

A label change like this is a reason to talk with your doctor, not a reason to panic or to quit on your own. We are a kitchen, not a clinic, so we stay in our lane: portioned, protein-forward meals with posted nutrition, so the food side of a GLP-1 routine is one less thing to worry about while you and your care team sort out the medicine side.

Frequently asked questions

What is NAION?

Non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front of the optic nerve drops. It usually causes sudden, painless vision loss in one eye, often noticed on waking. It is rare.

Which medicines get the new warning?

All GLP-1 receptor agonists, including Ozempic, Rybelsus and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), Trulicity, Victoza, Saxenda, Xultophy, Soliqua, generic exenatide and Foundayo (orforglipron).

Did the FDA say GLP-1 medicines cause NAION?

No. The FDA describes a potential increased risk. Trial and real-world data were limited and partly mixed, and conditions these drugs treat, such as diabetes, are themselves risk factors for NAION.

Should I stop my GLP-1 medicine?

Not on your own. The FDA told Healthline that patients with sudden, painless vision loss in one eye should contact their health care professional right away and should not stop their medicine without talking to their provider first.

Does food or diet affect this risk?

The FDA action does not address diet. Nothing in it suggests a food fix. Questions about your eyes belong with your doctor or an eye specialist.

Sources and credits

Follow the original sources for context and verification. A reference is not an endorsement of SmashMeals.

More SmashMeals news

Order Meals — View This Week's Menu